Recent work from our lab has evaluated uL3 clinical significance in p53-deleted colon cancer tissues and demonstrated that uL3 expression decrease is associated with malignant progression and tumor grade and correlated with the development of resistance to different chemotherapeutic agents such as 5-FU and OHP [32,58]. This evidence concerns the gene TP53 and malignant colon neoplasm.